Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: A randomized phase 2 PrECOG study (PrE0501)

Joseph Aisner, Judith B. Manola, Shaker R. Dakhil, Philip J. Stella, Mika A. Sovak, Joan H. Schiller

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

INTRODUCTION: After early reports of vandetanib's efficacy in the induction setting, we evaluated the effect of combination docetaxel, carboplatin, and vandetanib, followed by maintenance therapy with either vandetanib, or placebo on progression-free survival (PFS) in patients with advanced non-small-cell lung cancer. METHODS: Patients with advanced non-small-cell lung cancer were randomized to induction docetaxel (75 mg/m) + carboplatin (area under the curve of 6) on day 1 of a 21-day cycle, and daily vandetanib (100 mg/day orally) for four cycles, followed by daily vandetanib (300 mg/day orally) or placebo until progression. Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0 of 1, and no prior cytotoxic or targeted agents for advanced disease. RESULTS: One hundred sixty-two patients were randomized; 158 began induction treatment. Fifty-eight patients began maintenance vandetanib or placebo (median, 3.5 cycles). Median PFS for patients randomized to maintenance vandetanib was 4.5 months (95% confidence interval, 3.3-5.8 months), and for patients randomized to maintenance placebo was 4.2 months (95% confidence interval, 2.8-4.9 months). An exploratory analysis showed prolonged PFS for patients randomized to vandetanib maintenance (stratified log-rank p= 0.07) as also in a multivariate model adjusting for sex and stage (p= 0.02). Differences in PFS were not observed among patients who began maintenance therapy. Toxicities were similar to other studies of these agents. CONCLUSION: Neither arm showed improvement over historical median PFS of 4.6 months, although patients who began maintenance and were randomized to vandetanib had somewhat better outcomes than those randomized to placebo. Given its acceptable toxicity profile, there may be a role for vandetanib in maintenance.

Original languageEnglish (US)
Pages (from-to)1075-1083
Number of pages9
JournalJournal of Thoracic Oncology
Volume8
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Induction Chemotherapy
Non-Small Cell Lung Carcinoma
Placebos
Maintenance
Disease-Free Survival
docetaxel
Carboplatin
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
Confidence Intervals
Area Under Curve
Therapeutics

Keywords

  • Maintenance therapy
  • Non?small-cell lung cancer
  • Vandetanib

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer : A randomized phase 2 PrECOG study (PrE0501). / Aisner, Joseph; Manola, Judith B.; Dakhil, Shaker R.; Stella, Philip J.; Sovak, Mika A.; Schiller, Joan H.

In: Journal of Thoracic Oncology, Vol. 8, No. 8, 08.2013, p. 1075-1083.

Research output: Contribution to journalArticle

Aisner, Joseph ; Manola, Judith B. ; Dakhil, Shaker R. ; Stella, Philip J. ; Sovak, Mika A. ; Schiller, Joan H. / Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer : A randomized phase 2 PrECOG study (PrE0501). In: Journal of Thoracic Oncology. 2013 ; Vol. 8, No. 8. pp. 1075-1083.
@article{936c472b66fa4a6dbc67a62d716b8cea,
title = "Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: A randomized phase 2 PrECOG study (PrE0501)",
abstract = "INTRODUCTION: After early reports of vandetanib's efficacy in the induction setting, we evaluated the effect of combination docetaxel, carboplatin, and vandetanib, followed by maintenance therapy with either vandetanib, or placebo on progression-free survival (PFS) in patients with advanced non-small-cell lung cancer. METHODS: Patients with advanced non-small-cell lung cancer were randomized to induction docetaxel (75 mg/m) + carboplatin (area under the curve of 6) on day 1 of a 21-day cycle, and daily vandetanib (100 mg/day orally) for four cycles, followed by daily vandetanib (300 mg/day orally) or placebo until progression. Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0 of 1, and no prior cytotoxic or targeted agents for advanced disease. RESULTS: One hundred sixty-two patients were randomized; 158 began induction treatment. Fifty-eight patients began maintenance vandetanib or placebo (median, 3.5 cycles). Median PFS for patients randomized to maintenance vandetanib was 4.5 months (95{\%} confidence interval, 3.3-5.8 months), and for patients randomized to maintenance placebo was 4.2 months (95{\%} confidence interval, 2.8-4.9 months). An exploratory analysis showed prolonged PFS for patients randomized to vandetanib maintenance (stratified log-rank p= 0.07) as also in a multivariate model adjusting for sex and stage (p= 0.02). Differences in PFS were not observed among patients who began maintenance therapy. Toxicities were similar to other studies of these agents. CONCLUSION: Neither arm showed improvement over historical median PFS of 4.6 months, although patients who began maintenance and were randomized to vandetanib had somewhat better outcomes than those randomized to placebo. Given its acceptable toxicity profile, there may be a role for vandetanib in maintenance.",
keywords = "Maintenance therapy, Non?small-cell lung cancer, Vandetanib",
author = "Joseph Aisner and Manola, {Judith B.} and Dakhil, {Shaker R.} and Stella, {Philip J.} and Sovak, {Mika A.} and Schiller, {Joan H.}",
year = "2013",
month = "8",
doi = "10.1097/JTO.0b013e3182937317",
language = "English (US)",
volume = "8",
pages = "1075--1083",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "8",

}

TY - JOUR

T1 - Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer

T2 - A randomized phase 2 PrECOG study (PrE0501)

AU - Aisner, Joseph

AU - Manola, Judith B.

AU - Dakhil, Shaker R.

AU - Stella, Philip J.

AU - Sovak, Mika A.

AU - Schiller, Joan H.

PY - 2013/8

Y1 - 2013/8

N2 - INTRODUCTION: After early reports of vandetanib's efficacy in the induction setting, we evaluated the effect of combination docetaxel, carboplatin, and vandetanib, followed by maintenance therapy with either vandetanib, or placebo on progression-free survival (PFS) in patients with advanced non-small-cell lung cancer. METHODS: Patients with advanced non-small-cell lung cancer were randomized to induction docetaxel (75 mg/m) + carboplatin (area under the curve of 6) on day 1 of a 21-day cycle, and daily vandetanib (100 mg/day orally) for four cycles, followed by daily vandetanib (300 mg/day orally) or placebo until progression. Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0 of 1, and no prior cytotoxic or targeted agents for advanced disease. RESULTS: One hundred sixty-two patients were randomized; 158 began induction treatment. Fifty-eight patients began maintenance vandetanib or placebo (median, 3.5 cycles). Median PFS for patients randomized to maintenance vandetanib was 4.5 months (95% confidence interval, 3.3-5.8 months), and for patients randomized to maintenance placebo was 4.2 months (95% confidence interval, 2.8-4.9 months). An exploratory analysis showed prolonged PFS for patients randomized to vandetanib maintenance (stratified log-rank p= 0.07) as also in a multivariate model adjusting for sex and stage (p= 0.02). Differences in PFS were not observed among patients who began maintenance therapy. Toxicities were similar to other studies of these agents. CONCLUSION: Neither arm showed improvement over historical median PFS of 4.6 months, although patients who began maintenance and were randomized to vandetanib had somewhat better outcomes than those randomized to placebo. Given its acceptable toxicity profile, there may be a role for vandetanib in maintenance.

AB - INTRODUCTION: After early reports of vandetanib's efficacy in the induction setting, we evaluated the effect of combination docetaxel, carboplatin, and vandetanib, followed by maintenance therapy with either vandetanib, or placebo on progression-free survival (PFS) in patients with advanced non-small-cell lung cancer. METHODS: Patients with advanced non-small-cell lung cancer were randomized to induction docetaxel (75 mg/m) + carboplatin (area under the curve of 6) on day 1 of a 21-day cycle, and daily vandetanib (100 mg/day orally) for four cycles, followed by daily vandetanib (300 mg/day orally) or placebo until progression. Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0 of 1, and no prior cytotoxic or targeted agents for advanced disease. RESULTS: One hundred sixty-two patients were randomized; 158 began induction treatment. Fifty-eight patients began maintenance vandetanib or placebo (median, 3.5 cycles). Median PFS for patients randomized to maintenance vandetanib was 4.5 months (95% confidence interval, 3.3-5.8 months), and for patients randomized to maintenance placebo was 4.2 months (95% confidence interval, 2.8-4.9 months). An exploratory analysis showed prolonged PFS for patients randomized to vandetanib maintenance (stratified log-rank p= 0.07) as also in a multivariate model adjusting for sex and stage (p= 0.02). Differences in PFS were not observed among patients who began maintenance therapy. Toxicities were similar to other studies of these agents. CONCLUSION: Neither arm showed improvement over historical median PFS of 4.6 months, although patients who began maintenance and were randomized to vandetanib had somewhat better outcomes than those randomized to placebo. Given its acceptable toxicity profile, there may be a role for vandetanib in maintenance.

KW - Maintenance therapy

KW - Non?small-cell lung cancer

KW - Vandetanib

UR - http://www.scopus.com/inward/record.url?scp=84880923313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880923313&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e3182937317

DO - 10.1097/JTO.0b013e3182937317

M3 - Article

C2 - 23689430

AN - SCOPUS:84880923313

VL - 8

SP - 1075

EP - 1083

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 8

ER -